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Aspirin has potential benefits for primary 
prevention of cardiovascular outcomes 
in diabetes: updated literature-based 
and individual participant data meta-analyses 
of randomized controlled trials
Samuel Seidu1,2* , Setor K. Kunutsor3,4, Howard D. Sesso5,6, J. M. Gaziano6, J. E. Buring5, 
Maria Carla Roncaglioni7 and Kamlesh Khunti1,2
Abstract 
Background: The clinical benefit of aspirin for the primary prevention of cardiovascular disease (CVD) in diabetes 
remains uncertain. To evaluate the efficacy and safety of aspirin for the primary prevention of cardiovascular out-
comes and all-cause mortality events in people with diabetes, we conducted an updated meta-analysis of published 
randomised controlled trials (RCTs) and a pooled analysis of individual participant data (IPD) from three trials.
Methods: Randomised controlled trials of aspirin compared with placebo (or no treatment) in participants with 
diabetes with no known CVD were identified from MEDLINE, Embase, Cochrane Library, and manual search of 
bibliographies to January 2019. Relative risks with 95% confidence intervals were used as the summary measures of 
associations.
Results: We included 12 RCTs based on 34,227 participants with a median treatment duration of 5.0 years. Com-
paring aspirin use with no aspirin, there was a significant reduction in risk of major adverse cardiovascular events 
(MACE)0.89 (0.83–0.95), with a number needed to treat (NNT)of 95 (95% CI 61 to 208) to prevent one MACE over 
5 years average follow-up. Evidence was lacking of heterogeneity and publication bias among contributing trials for 
MACE. Aspirin use had no effect on other endpoints including all-cause mortality; however, there was a significant 
reduction in stroke for aspirin dosage ≤ 100 mg/day 0.75 (0.59–0.95). There were no significant effects of aspirin use 
on major bleeding and other bleeding events, though some of the estimates were imprecise. Pooled IPD from the 
three trials (2306 participants) showed no significant evidence of an effect of aspirin on any of the outcomes evalu-
ated; however, aspirin reduced the risk of MACE in non-smokers 0.70 (0.51–0.96) with a NNT of 33 (95% CI 20 to 246) 
to prevent one MACE.
Conclusions: Aspirin has potential benefits in cardiovascular primary prevention in diabetes. The use of low dose 
aspirin may need to be individualised and based on each individual’s baseline CVD and bleeding risk.
Systematic review registration PROSPERO: CRD42019122326
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Introduction
Cardiovascular disease (CVD)accounts for more than 
70% of deaths in people with diabetes and is the lead-
ing cause of mortality in these patients [1]. Low-dose 
aspirin has commonly been used in the treatment and 
prevention of CVD and its effectiveness for the second-
ary prevention of CVD in people with diabetes is well 
established [2]. However, the balance of the benefits and 
harms of aspirin for primary CVD prevention in diabetes 
has been widely studied and still controversial. Follow-
ing the Antithrombotic Treatment Trialists’ Collabora-
tion 2009 meta-analysis of individual participant data 
(IPD) from six primary prevention trials which reported 
a non-significant reduction in serious vascular events in 
people with diabetes; [3] several other meta-analyses in 
people with diabetes have reported no significant benefit 
for aspirin in primary CVD prevention [4–7]. Recom-
mendations from various guideline bodies on the use of 
aspirinin people with diabetes have not been consist-
ent. Where as guidelines of the Fifth Joint Task Force 
of the European Society of Cardiology and Other Soci-
eties do not provide specific recommendations for the 
use of aspirin in people with diabetes [8], those by the 
American Diabetes Association (ADA), the American 
Heart Association (AHA), and the American College of 
Cardiology Foundation (ACCF) recommend the use of 
low-dose aspirin for the primary prevention of CVD in 
adults with diabetes, based on their individual baseline 
CVD risk and risk for bleeding [5]. In a recent updated 
meta-analysis of 10 trials published by our group [9], the 
data suggested a modest potential benefit of aspirin in 
the primary prevention of major adverse cardiovascular 
events (MACE) in people with diabetes; there was also an 
increase in the risk of major or gastrointestinal bleeding 
events, but estimates were imprecise and not significant. 
Our absolute risk reduction estimates and the potential 
for an increased risk of major bleeding events suggested 
that the benefits might not exceed the harms. Our rec-
ommendation was that further evidence was required.
In 2018, three separate landmark trials were published 
on role of aspirin in the primary prevention of CVD 
and these included (i) A Study of Cardiovascular Events 
in Diabetes (ASCEND); [10] (ii) Aspirin to Reduce Risk 
of Initial Vascular Events (ARRIVE); [11] and (iii) Aspi-
rin in Reducing Events in the Elderly (ASPREE) [12]. 
The ASCEND and ASPREE trials assessed the effects of 
aspirin therapy in adults with diabetes mellitus exclu-
sively and as a subgroup respectively. In the ASCEND 
trial, aspirin use reduced serious vascular events, but was 
associated with major bleeding events; whereas in the 
ASPREE trial, there was no differential effects of aspirin 
on the risk of CVD and bleeding in people with diabetes. 
Given the overall evidence, it appears the role of low-dose 
aspirin as a primary CVD prevention strategy in people 
with diabetes is still unresolved. Whether the potential 
benefits of aspirin for CVD primary prevention in dia-
betes is greater in those with high or low baseline CVD 
risk is also debated. Guidelines by the ADA recommend 
the use of low-dose aspirin for the primary prevention 
of CVD in adults who are at increased CVD risk, whilst 
not recommended for people at low CVD risk [13]. How-
ever, data from our previous review [9] and the ASPREE 
trial did not clearly support guidelines that encouraged 
the use of aspirin for the primary prevention of CVD in 
adults with diabetes at high CVD risk.
Given the persisting uncertainties on the benefits and 
harms of aspirin for the primary prevention of CVD in 
people with diabetes, we sought to update the evidence 
by conducting an updated meta-analysis of the literature. 
To enable comparison of the effectiveness of aspirin with 
placebo (or no treatment) under relevant clinical charac-
teristics not collected by the literature-based meta-anal-
ysis, we also conducted an (Individual Patient Data) IPD 
meta-analysis of three trials that were able to share their 
data.
Methods
Data sources and search strategy
We conducted this literature-based review and IPD 
using an updated protocol registered in the PROSPERO 
International prospective register of systematic reviews 
(CRD42019122326) and in accordance with guidelines of 
PRISMA (Additional file 1: Appendix S1) [14], PRISMA-
IPD (Additional file  1: Appendix S2) [15], methods rec-
ommended by the IPD Meta-analysis Methods Group of 
the Cochrane Collaboration [16], and guidance of Riley 
and colleagues [17]. We searched MEDLINE, Embase, 
and The Cochrane Library for randomised controlled 
trials (RCTs) published from November, 2015 (date of 
the last search of our previous review [9]) to 29 January 
2019. The computer-based searches combined free text 
and medical subject headings and combination of key 
words related to aspirin and diabetes, with no restric-
tions placed on language. The full details of the search 
strategy are provided in Additional file  1: Appendix S3. 
The titles and abstracts of all articles identified by the 
literature search were initially screened to assess their 
suitability for inclusion, after which we acquired poten-
tially relevant articles for detailed full text evaluation. 
Two reviewers (SKK and SS) independently conducted 
full text evaluation using the inclusion criteria and any 
disagreements regarding eligibility of an article was dis-
cussed. We also searched reference lists of selected stud-
ies and relevant reviews for additional publications. No 
separate ethical approval was required for the conduct of 
this study, as any necessary ethical approval was obtained 
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for each of the individual studies contributing data to the 
meta-analysis.
Study selection and eligibility criteria
Intervention studies were eligible if they met the follow-
ing inclusion criteria: (i) were randomised controlled, 
open or blinded trials; (ii) assessed the effects of aspi-
rin therapy compared to a placebo or no treatment; (iii) 
enrolled adults with diabetes mellitus (either exclusively 
or as a subgroup) without previous history or clinical 
evidence of CVD; (iv) reported data on cardiovascular 
endpoints, all-cause mortality, or other adverse events 
such as bleeding, cancer etc.; and (v) and had a follow-
up duration of at least a year. Studies that were non-
randomised comparing aspirin with another antiplatelet 
agent, included people with known CVD, or were sec-
ondary publications of trials already included in the anal-
ysis were excluded from the review.
Data extraction and quality assessment
One author (SKK) initially conducted the data extraction 
using a standardized data collection form and a second 
author (SS) independently checked the extracted data 
with that in the original articles. Data were extracted on 
the following characteristics: study design; patient char-
acteristics, intervention and comparison, and outcomes. 
The risk of bias assessment was conducted using the 
Cochrane Collaboration’s risk of bias tool [18].
Outcomes
The primary outcomes were MACE) [defined as com-
posite of nonfatal myocardial infarction (MI), nonfatal 
stroke, and cardiovascular death] and all-cause mortal-
ity. Secondary outcomes included (i) other cardiovascu-
lar endpoints (nonfatal MI, coronary heart disease death, 
fatal and nonfatal stroke, revascularization, sudden coro-
nary death, and transient ischaemic attack) and adverse 
events (any bleeding, gastro-intestinal bleeding, cancer, 
allergic reactions, and arrhythmias). Cardiovascular out-
comes used in trials and their ascertainment are reported 
in Additional file 1: Appendix S4.
Aspirin in Primary Prevention of cArdiovasculardIseaSe 
in diabEtes (APPRAISE) IPD meta‑analysis consortium
Investigators of eligible trials identified by the litera-
ture search strategy and well-known investigators in 
the field, were contacted by email, letter or phone, pro-
vided with a summary of the study protocol, and invited 
to join the collaboration if they had the relevant data 
available. Investigators expressing interest to collaborate 
in this effort were then provided with full details of the 
study protocol and a list of relevant study variables that 
could be used in the analyses. Data from each study were 
obtained using a standardised spreadsheet or in STATA 
format. The raw data were examined and inconsisten-
cies or irregularities were clarified with the investigators. 
Individual level data collected was coded and entered 
into a single database.
Statistical analysis
For the literature-based meta-analysis, summary meas-
ures were presented as relative risks (RRs) with 95% 
confidence intervals (CIs). Following Cornfield’s rare 
disease assumption [19], reported hazard ratios (HRs) 
and odds ratios (ORs) were assumed to approximate the 
same measure of RRs. We used reported RRs or calcu-
lated study specific unadjusted RRs based on raw events. 
To minimize the effect of heterogeneity, random-effects 
models was used to pool RRs. Heterogeneity across 
studies was assessed using the Cochrane χ2 statistic and 
the I2 statistic [20]. Study level characteristics including 
geographical location, sex differences, allocation con-
cealment, baseline CVD risk, dose of aspirin, compli-
ance, duration of treatment, and number of outcomes 
were prespecified as characteristics for assessment of 
heterogeneity, which were evaluated using stratified 
analysis and random effects meta-regression. For com-
parisons involving 10 or more studies, publication bias 
was assessed by visually inspecting a funnel plot and 
applying Egger’s regression symmetry test [21].
In the IPD meta-analysis, since not all trials provided 
time to event data, effects of the intervention on out-
comes were expressed as ORs using logistic regression 
analysis in the main analysis. Cox proportional hazards 
models were used for time to event data in supplementary 
analyses. We employed a one-step IPD meta-analyses 
in which IPD from all studies were modelled simultane-
ously with fixed effects, adjusting for age and trial arm to 
obtain the pooled intervention effect with a 95% CI. To 
contextualise our results, we also calculated the number 
needed to treat (NNT) using the formula: NNT = 1/abso-
lute risk reduction (ARR). The ARR was derived by mul-
tiplying the control risk by the relative risk reduction. All 
statistical analyses were performed with Stata release 15 
(StataCorp, College Station, Texas, USA).
Results
Literature‑based meta‑analysis
Study identification and selection
The systematic search of databases and manual scan-
ning of reference lists from November 2015 to January 
2019 identified 68 potentially relevant articles. Follow-
ing screening based on titles and abstracts, three arti-
cles remained for further evaluation. Following detailed 
full text evaluation, one was excluded. The remaining 
two articles plus 10 articles identified from our previous 
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review yielded a total of 12 unique trials for the meta-
analysis [10, 12, 22–31], which in aggregate comprised of 
34,227 participants with diabetes (Fig. 1).
Study characteristics and quality
Key characteristics of the 12 eligible trials published 
between 1988 and 2018 are reported in Table  1. Eight 
trials were double-blinded and the remaining were 
open label trials. The trials were conducted in different 
geographical locations: Five in Europe (UK and Italy); 
three in North America (USA); two in Asia (Japan); one 
recruited participants from both USA and Australia and 
another from 26 countries in Europe, North and South 
America, and Asia. The baseline average age of trial 
participants ranged from 18 to 90 years. There was vari-
ability in study populations ranging from participants 
at low to high cardiovascular risk: healthy community 
dwelling participants, those with pre-existing conditions 
such as hypertension, and those with multiple atheroscle-
rotic risk factors. Only four trials were conducted spe-
cifically in people with diabetes and the remaining eight 
were based on data from subgroup analysis in people 
with diabetes. The Early Treatment Diabetic Retinopathy 
Study (ETDRS) trial made a distinction between type 1 
and type 2 diabetes in their results and also included a 
small proportion of people with pre-existing CVD [24]. 
In the ASCEND trial, over 94% of study participants 
were reported to have type 2 diabetes [10]. The dosage of 
68 Potentially relevant citations identified 
from MEDLINE, Embase, and Cochrane 
library from November 2015
65 excluded on the basis of title 
and/ or abstract
1 excluded on the basis of:
Was based on a long-term follow-
up of one of the trials included in 
previous review and had no 
usable data for the current 
analysis
2 articles eligible for analyses
3 Full-text articles retrieved for more 
detailed evaluation
Id
en
tif
ic
at
io
n
Sc
re
en
in
g
El
ig
ib
ilit
y
In
cl
ud
ed
12 articles comprising of 12 unique 
trials eligible for pooled analysis
10 articles comprising of 10 
unique trials eligible for analyses 
from previous review
12 articles contributed published 
data for literature-based meta-
analysis
3 trials contributed individual level 
data for pooled analysis
Fig. 1 PRISMA flow diagram
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aspirin ranged from 75 mg to 650 mg daily. Medication 
compliance or adherence was reported in seven trials 
using a variety of subjective (self-reports) and objective 
(biochemical monitoring and pill counts) measures and 
average values ranged from 50.0 to 91.8%. The ASPREE 
trial reported that approximately two-thirds of par-
ticipants were still taking their assigned intervention 
at the end of the trial [12]. The average follow-up times 
of included trials ranged from 3.6 to 10.1  years and the 
overall median (interquartile range) follow-up time was 
5.0 (4.5–6.7) years. Eight trials demonstrated a high 
risk of bias within one to three areas of study quality, as 
assessed using the Cochrane Collaboration tool (Addi-
tional file  1: Appendix S5). Majority of the trials had a 
high risk of bias for selective reporting. Only two trials 
were found to have a low risk of bias in all areas and eight 
trials had an unclear risk of bias in one or more areas of 
study quality.
Major cardiovascular outcomes and all‑cause mortality
Relative risks for cardiovascular outcomes and all-cause 
mortality events comparing aspirin therapy with pla-
cebo or no treatment in pooled analyses are reported 
in Fig. 2 and Appendices S6–S12. In 10 trials of MACE 
(34,058 participants and 3104 events), aspirin therapy 
significantly reduced the risk of MACE compared with 
placebo or no treatment 0.89 (95% CI 0.83 to 0.95). Using 
a fixed effects model, the pooled RR remained unchanged 
(Additional file  1: Appendix S6). There was no evi-
dence of heterogeneity between the contributing studies 
(I2= 0%, 0 to 62%; p > 0.99). On exclusion of the ETDRS 
trial which involved a small proportion of patients with 
previous CVD, the pooled RR remained the same 0.89 
(95% CI 0.82 to 0.96) (Additional file 1: Appendix S7).
Aspirin therapy was not associated with a significant 
decrease in risk of all-cause mortality (eight trials; 27,102 
participants and 2776 events) 0.95 (95% CI 0.88 to 1.02) 
and there was no evidence of heterogeneity between con-
tributing studies (I2= 0%, 0 to 68%; p = 0.88) (Fig. 2; Addi-
tional file 1: Appendix S8).
In seven trials of MI and five trials of CHD, aspirin 
therapy was not associated with a significant reduction in 
risk of any of these outcomes: 0.84 (95% CI 0.64 to 1.11)
and 0.98 (95% CI 0.79 to 1.21) respectively (Fig. 2; Addi-
tional file 1: Appendices S9, S10). There was evidence of 
moderate heterogeneity (I2= 57%, 1 to 82%; p = 0.03) for 
the MI analysis and no evidence of heterogeneity (I2= 0%, 
0 to 79%; p = 0.75) for the CHD analysis.
There was no significant reduction in the risk of stroke 
or CVD death when aspirin therapy was compared with 
MACE
All cause mortality
Myocardial infarction
CHD
Stroke
CVD death
Outcome
10
8
7
5
9
6
No. of studies
1,467 / 17,028
1,359 / 13,578
422 / 5,816
156 / 2,750
221 / 5,914
518 / 12,767
Aspirin
Events / Participants
1,637 / 17,030
1,417 / 13,524
457 / 5,802
156 / 2,735
236 / 5,873
571 / 12,771
Control or placebo
Events / Participants
0.89 (0.83, 0.95)
0.95 (0.88, 1.02)
0.84 (0.64, 1.11)
0.98 (0.79, 1.21)
0.88 (0.72, 1.08)
0.92 (0.78, 1.08)
RR (95% CI)
Favours aspirin  Favours control or placebo 
1.5 .75 1.5
Fig. 2 Effect of aspirin on the primary prevention of major adverse cardiovascular events, all-cause mortality, myocardial infarction, coronary 
heart disease, stroke, and cardiovascular disease death, in people with diabetes. CI, confidence interval (bars); CHD, coronary heart disease; CVD, 
cardiovascular disease; MACE, major adverse cardiovascular events; RR, relative risk
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placebo or no treatment: 0.88 (95% CI 0.72 to 1.08) and 
0.92 (95% CI 0.78 to 1.08;) respectively (Fig. 2; Additional 
file 1: Appendices S11, S12). There was no significant evi-
dence of heterogeneity between the contributing studies 
for stroke or CVD death: (I2= 10%, 0 to 68%; p = 0.35) 
and (I2= 23%, 0 to 67%; p = 0.26) respectively.
Other cardiovascular outcomes
There was no significant difference in the risk of other 
cardiovascular outcomes such as nonfatal MI, CHD 
death, fatal stroke, nonfatal stroke, ischaemic stroke, 
haemorrhagic stroke, CVD, revascularization, angina 
pectoris, sudden coronary death, and TIA, when aspi-
rin was compared with placebo or no treatment (Fig. 3; 
Additional file 1: Appendix S13).
Subgroup analysis
There was no evidence of effect modification by any of 
the clinically relevant study-level characteristics explored 
for the outcomes of MACE, all-cause mortality, and CVD 
death (Additional file  1: Appendices S14–S18). For MI, 
the moderate heterogeneity between studies contribut-
ing to pooled analysis seemed to be partly explained by 
treatment duration (p value for meta-regression = 0.01). 
Compared to participants with treatment duration 
more than 5 years, participants with treatment duration 
of 5  years or less had a significantly reduced risk of MI 
with aspirin use 0.70 (95% CI 0.53 to 0.93) (Additional 
file  1: Appendix S16). There was also evidence of effect 
modification by aspirin dosage (p value for meta-regres-
sion = 0.02) and treatment duration (p value for meta-
regression = 0.02) for the effect of aspirin use on stroke. 
The risk of stroke was significantly reduced for trials 
using aspirin dosage of 100 mg per day or less compared 
to more than 100 mg per day. Similarly, compared to par-
ticipants with treatment duration of 5 years or less, par-
ticipants with treatment duration of more than 5  years 
had a significantly reduced risk of stroke with aspirin 
(Additional file 1: Appendix S17).
Adverse effects
Figure  4 presents pooled RRs of the effects of aspi-
rin therapy compared with placebo or no treatment on 
adverse outcomes such as major bleeding, gastrointes-
tinal bleeding, non-gastrointestinal bleeding, cancer, 
venous thromboembolism, gastrointestinal symptoms, 
Nonfatal MI
CHD death
Fatal stroke
Nonfatal stroke
Ischaemic stroke
Hemorrhagic stroke
CVD
Revascularization
Angina pectoris
TIA
Sudden cardiac death
Outcome
3
2
4
1
4
3
2
3
3
4
1
No. of studies
258 / 9,640
140 / 8,378
72 / 11,496
29 / 638
252 / 9,791
62 / 9,538
74 / 1,546
365 / 8,897
99 / 2,419
194 / 10,159
47 / 1,856
Aspirin
Events / Participants
260 / 9,655
148 / 8,378
73 / 11,510
41 / 638
289 / 9,788
50 / 9,512
77 / 1,542
418 / 8,890
115 / 2,427
235 / 10,167
67 / 1,855
Control or placebo
Events / Participants
0.99 (0.84, 1.18)
1.02 (0.66, 1.57)
1.01 (0.73, 1.40)
0.71 (0.44, 1.14)
0.82 (0.55, 1.23)
1.24 (0.85, 1.80)
0.98 (0.71, 1.34)
0.87 (0.75, 1.00)
0.87 (0.66, 1.13)
0.82 (0.68, 1.00)
0.70 (0.49, 1.01)
RR (95% CI)
Favours aspirin  Favours control or placebo 
1.25 .5 .75 1.5 2.5
Fig. 3 Effect of aspirin on the primary prevention of individual cardiovascular disease endpoints in people with diabetes. CHD, coronary heart 
disease; CI, confidence interval (bars); CVD, cardiovascular disease; MI, myocardial infarction; RR, relative risk; TIA, transient ischaemic attack
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arrhythmias, and allergy. No statistically significant dif-
ference in risk was found for any of these outcomes.
Absolute benefits and harms
The ARR of MACEin people with diabetes associated 
with aspirin use was 1.06% (95% CI 0.48 to 1.63)over the 
average follow-up period of 5 years, which translates into 
a NNT of 95 (95% CI 61 to 208) to prevent one MACE. 
For MI in participants with a treatment duration of 
5 years or less, the ARR and NNT were 2.26 (95% CI 0.53 
to 3.55) and 44 (95% CI 28 to 189) respectively. For the 
risk of stroke with aspirin dosage of 100  mg per day or 
less, the ARR and NNT were 0.99 (95% CI 0.20 to 1.62) 
and 101 (95% CI 62 to 507) respectively. For the risk of 
stroke with treatment duration of more than 5 years, the 
ARR and NNT were 2.41 (95% CI 0.62 to 3.64) and 42 
(95% CI 27 to 172) respectively.
Publication bias
A funnel plot for the comparison that involved 10 studies 
(MACE) was symmetrical (Additional file  1: Appendix 
S19) which was consistent with Egger’s regression sym-
metry test (p = 0.99). In addition, there was no defini-
tive evidence of selective reporting when studies were 
grouped by size in meta-regression analysis (Additional 
file 1: Appendix S14).
Analysis of IPD of RCTs
Investigators of 10 trials were contacted to contrib-
ute data to the APPRAISE consortium. Of these 10, 
we obtained IPD data from three RCTs namely: Physi-
cians’ Health Study (PHS); Primary Prevention Project 
(PPP); and the Women’s Health Study (WHS). Details 
of contributing trials are presented in Additional file  1: 
Appendix S20. The three RCTs comprised of 2306 par-
ticipants of which 1188 were randomised to the aspirin 
group and 1118 to the placebo group (Table  2). Over-
all the mean (standard deviation, SD) age was 60.1 (8.7) 
years and 38.5% were male. The median (interquar-
tile range) duration of follow-up was 9.5 (5.2–10.4) was 
years (based on data from two trials). The trial groups 
had similar cardiovascular risk profiles. In pooled analy-
sis of the three trials, there was no significant evidence 
of an effect of aspirin on MACE, all-cause mortality, MI, 
stroke, or CVD death (Fig. 5). In pooled analysis of two 
trials (PHS and WHS) with time to event data, there was 
no significant difference in risk for any of the outcomes 
assessed (Additional file  1: Appendix S21). There was 
Major bleeding
GI bleeding
Non-GI bleeding
Bleeding in eye
GI symptoms
Cancer
Arrhythmias
Allergy
Amputation
VTE
Adverse events
6
4
2
1
2
3
2
1
2
1
No. of studies
534 / 13,042
185 / 10,159
120 / 1,900
57 / 7740
99 / 1,900
966 / 10,234
281 / 8,378
72 / 638
136 / 9,596
93 / 7,740
Aspirin
Events / Participants
450 / 13,052
137 / 10,167
98 / 1,915
64 / 7740
94 / 1,915
969 / 10,233
276 / 8,378
64 / 638
159 / 9,595
117 / 7,740
Control or placebo
Events / Participants
1.30 (0.92, 1.82)
1.48 (0.87, 2.49)
2.91 (0.20, 41.94)
0.89 (0.62, 1.27)
5.07 (0.08, 316.25)
0.98 (0.86, 1.12)
1.02 (0.87, 1.21)
1.14 (0.80, 1.63)
0.86 (0.68, 1.08)
0.79 (0.61, 1.03)
RR (95% CI)
Favours aspirin  Favours control or placebo 
1.05 .1 .25 .5 2.5 5 7.5 15 30
Fig. 4 Effect of aspirin on adverse events in people with diabetes. CI, confidence interval (bars); GI, gastro-intestinal; RR, relative risk; VTE, venous 
thromboembolism
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significant evidence of a differential effect of aspirin on 
the risk of MACE by smoking status ((p value for meta-
regression = 0.01) (Fig. 6). Aspirin use reduced the risk of 
MACE in non-smokers 0.70 (95% CI 0.51 to 0.96) com-
pared to those who smoked 1.77 (95% CI 0.91 to 3.45). 
The ARR of MACE in non-smokers associated with aspi-
rin use was 3.04% (95% CI 0.41 to 4.97) over the aver-
age follow-up period of 10 years, which translates into a 
NNT of 33 (95% CI 20 to 246) to prevent one MACE.
Discussion
Key findings
Using a literature-based meta-analysis and pooled analy-
sis of individual level data from the PHS, PPP, and WHS 
trials, we have evaluated the efficacy and safety of aspirin 
for the primary prevention of cardiovascular outcomes 
and all-cause mortality events among people with diabe-
tes. Compared with no aspirin, aspirin use was associated 
with an 11% reduction in the risk of MACE (which was 
a combination of cardiovascular mortality, nonfatal MI, 
and nonfatal stroke outcomes). Aspirin use however no 
effect on other cardiovascular endpoints and all-cause 
mortality. Heterogeneity was generally low or absent 
between contributing studies for majority of outcomes, 
except for the MI comparison which was characterised 
by moderate heterogeneity. Except for MI and stroke, 
there were no differential effects of aspirin on other out-
comes by the pre-specified clinically relevant character-
istics including baseline cardiovascular risk. Aspirin use 
was associated with a 30% reduction in the risk of MI for 
a treatment duration of 5 years or less, but no benefit for 
a treatment duration of more than 5  years. In addition, 
aspirin use reduced the risk of stroke for a lower inter-
vention dose (≤ 100 mg/day) and longer treatment dura-
tion (> 5 years). In the context of multiple statistical tests 
for interaction conducted, the results of the subgroup 
analyses should be interpreted with caution and may 
require replication in further studies. There were sugges-
tions that aspirin use might be associated with adverse 
effects such as major bleeding, gastrointestinal symp-
toms, and arrhythmias, but the estimates were imprecise 
and not significant. The effects of aspirin on cancer and 
venous thromboembolism outcomes were also not signif-
icant. Finally, pooled analysis of individual level data from 
three trials showed no significant evidence of an effect of 
aspirin on any of the outcomes evaluated. However, aspi-
rin use was associated with a 30% reduction in the risk of 
MACE in non-smokers; with a suggestion of an increased 
risk of MACE in smokers, though the risk estimate in this 
group was based on only 46 events and was imprecise 
and should be interpreted with caution. These findings 
may reflect evidence that cigarette smoking causes an 
increase in platelet aggregability [32, 33], hence aspirin 
may not effectively inhibit platelet activity in smokers. It 
has been reported that smokers may be about 12 times 
resistant to the effects of aspirin. An established body of 
literature suggests that the reduced antiplatelet effect of 
aspirin is associated with a fourfold increase in the risk of 
adverse cardiovascular events [34, 35].
Comparison with previous work
The current study builds on previous meta-analyses 
including one of ours [4–7, 9]. Since the publication of 
the ASCEND-A Study of Cardiovascular Events in Dia-
betes and ASPREE-Aspirin in Reducing Events in the 
Elderly trials in 2018, a number of reviews have recently 
been published. In one review which was based on the 
overall population and not specifically in people with 
diabetes [36], Zheng and Roddick in a subsidiary analy-
sis reported data for participants with diabetes based on 
10 studies. In their report, aspirin therapy was associated 
with a reduction in the primary composite cardiovascu-
lar outcome (MACE) based on pooled analysis of seven 
trials, but not with any of the secondary cardiovascular 
outcomes. In addition, they reported increases in major 
and gastrointestinal intestinal bleeding. In a research 
letter, Fortuni and colleagues included only five trials 
in their pooled analysis and reported similar findings 
Table 2 Key characteristics of  participants at  baseline 
in three trials that contributed individual participant data
* Data contributed by two trials; values are mean (SD), median (IQR), or n (%); MI, 
myocardial infarction; rheumatoid arthritis
Characteristic Aspirin group
(N = 1188)
Placebo group
(N = 1118)
Age (years) 60.1 (8.9) 60.1 (8.6)
Male sex 455 (38.3) 433 (38.7)
Body mass index (kg/m2) 28.8 (5.7) 29.1 (6.0)
Systolic blood pressure (mmHg) 134.8 (14.4) 134.7 (13.8)
Total cholesterol (mmol/l)* 5.66 (1.20) 5.41 (1.16)
Smoking status
 Other 1015 (85.5) 966 (86.5)
 Current 172 (14.5) 151 (13.5)
History of hypertension
 No 469 (39.5) 453 (40.7)
 Yes 718 (60.5) 661 (59.3)
Baseline treatment for hypertension*
 No 489 (61.4) 455 (61.6)
 Yes 307 (38.6) 284 (38.4)
Family history of MI*
 No 666 (84.0) 623 (84.2)
 Yes 127 (16.0) 117 (15.8)
History of RA
 No 898 (98.4) 842 (97.9)
 Yes 15 (1.6) 18 (2.1)
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to that of Zheng and Roddick [37]. Our current study 
which is based on pooled analysis of 12 trials is therefore 
an updated assessment of the topic and also includes a 
pooled analysis of IPD contributed by three trials. Con-
sistent with the recent and other previously published 
reviews on the topic [4–7, 9, 36], aspirin use reduced 
MACE with no differential effects of aspirin use on other 
cardiovascular endpoints as well as all-cause mortality. 
New findings by our current study include important dif-
ferences by aspirin dosage and treatment duration for the 
effect of aspirin use on the risk of MI and stroke and no 
effects of aspirin use on major bleeding and other adverse 
effects. Based on IPD contributed by three trials, we had 
the opportunity to re-evaluate the efficacy of aspirin for 
the specified outcomes in clinically relevant subgroups 
with suggestions of an important difference by smoking 
status for the effect of aspirin on the risk of MACE.
Implications of our findings
Compared with aspirin use for the secondary preven-
tion of vascular disease, the use of aspirin for primary 
prevention has been a widely debated and controversial 
topic. Two recently published landmark trials, ASCEND, 
and ASPREE, [10, 11] evaluated the efficacy and safety of 
aspirin for the primary prevention of cardiovascular out-
comes in people with diabetes and have been included 
in this review. Whereas the absolute benefits of aspirin 
on vascular benefits were counterbalanced by the bleed-
ing hazard in the ASCEND study, there was no differen-
tial effect of aspirin on the risk of CVD and bleeding in 
people with diabetes in the ASPREE trial. Though our 
results show aspirin may have a beneficial effect in the 
primary prevention of cardiovascular disease in people 
with diabetes, aspirin had no differential effect on bleed-
ing risk. Given the imprecise estimates reported for GI 
and non-GI bleeding, these results may be due to inade-
quate power of these trials to detect these events. Indeed, 
a wealth of data from general and secondary prevention 
populations suggests that the main adverse effect associ-
ated with aspirin use is GI bleeding [38]. Both low aspirin 
dosage and long term therapy is associated with an abso-
lute excess of GI bleeding complications in these popula-
tion groups [39]. A higher risk of bleeding events has also 
been reported among the elderly and people at low car-
diovascular risk [40]. Though the current data suggests 
otherwise, real-world data in general populations have 
MACE
All cause mortality
Myocardial infarction
Stroke
CVD death
Outcome
107 / 1187
98 / 1188
51 / 1187
36 / 1188
34 / 402
Aspirin
Events / Participants
114 / 1118
81 / 1118
56 / 1062
46 / 1118
36 / 395
Control or placebo
Events / Participants
0.86 (0.65, 1.14)
1.15 (0.84, 1.57)
0.84 (0.57, 1.25)
0.72 (0.46, 1.12)
1.40 (0.49, 3.98)
OR (95% CI)
Favours aspirin  Favours control or placebo 
1.25 .5 2.5 5
Fig. 5 Effect of aspirin on the primary prevention of major adverse cardiovascular events, all-cause mortality, myocardial infarction, stroke, and 
cardiovascular disease death in people with diabetes, based on pooled analysis of individual level data from three trials. CI, confidence interval 
(bars); CVD, cardiovascular disease; MACE, major adverse cardiovascular events; OR, odds ratio. BP, blood pressure; CI, confidence interval (bars); OR, 
odds ratio; RA, rheumatoid arthritis
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demonstrated higher rates of bleeding in people with dia-
betes on aspirin therapy [41]. Taking the overall findings 
together, two questions still remain on the role of aspirin 
therapy in primary prevention of CVD in diabetes: (i) are 
the absolute vascular benefits of aspirin counterbalanced 
by the potential for bleeding and (ii) in what groups of 
the population do the benefits of aspirin outweigh its 
bleeding hazards. Based on a recent comprehensive nar-
rative review by Lippi and colleagues, the authors suggest 
that the harms of aspirin in primary prevention of CVD 
may be larger than the benefits, especially in the elderly 
general population [42]. Our study findings suggest there 
may be important differences in the effect of aspirin by 
treatment dosage, treatment duration, as well as smoking 
status, but these results are based on limited data from 
subgroup analyses. Though our findings showed no sug-
gestions of differences in the effect of aspirin by gender 
on all outcomes evaluated, there is evidence suggest-
ing that the variation in the effect of aspirin therapy on 
cardiovascular outcomes could be explained by gender. 
In a meta-analysis of 23 trials which aimed to evaluate 
whether gender might play a role in explaining the large 
variation of aspirin efficacy across primary and second-
ary MI prevention trials, the authors demonstrated that 
gender accounted for a substantial proportion of the 
variability in the efficacy of aspirin in reducing MI rates 
across these trials [43]. Emerging evidence points to the 
fact that women have an increased risk of aspirin resist-
ance compared to men, which makes aspirin less effec-
tive in women [44]. Apart from the condition diabetes 
which is associated with reduced rates of responsive-
ness to aspirin [45], other factors that could potentially 
reduce the antiplatelet effect of aspirin include older age, 
obesity, renal insufficiency, and platelet count. To answer 
all these pertinent questions may require an IPD meta-
analysis based on all contributing trials. An updated 
meta-analysis by the Antithrombotic Trialists’ Collabo-
ration could help address some of these questions. There 
have been contradictory guideline recommendations on 
the role of aspirin in primary CVD prevention; however, 
the ADA recommends the use of low-dose aspirin for the 
primary prevention of CVD in adults with type 1 and 2 
Age (years)
< 60
≥ 60
Sex
Male
Female
Body mass index (kg/m2)
< 25.0
≥ 25.0
Systolic BP (mmHg)
< 140
≥ 140
Smoking status
No
Yes
Hx of hypertension
No
Yes
Hx of RA
No
Yes
Subgroup
50 / 589
57 / 598
42 / 455
65 / 732
20 / 222
72 / 585
44 / 492
43 / 292
76 / 1015
30 / 171
31 / 468
76 / 718
68 / 897
5 / 15
Aspirin
Events / Participants
51 / 567
63 / 551
46 / 433
68 / 685
27 / 194
73 / 558
47 / 454
51 / 274
98 / 966
16 / 151
36 / 453
78 / 661
71 / 842
5 / 18
Placebo or control
Events / Participants
0.94 (0.62, 1.42)
0.78 (0.53, 1.15)
0.81 (0.52, 1.28)
0.89 (0.62, 1.28)
0.64 (0.35, 1.20)
0.92 (0.64, 1.30)
0.86 (0.56, 1.33)
0.75 (0.48, 1.16)
0.70 (0.51, 0.96)
1.77 (0.91, 3.45)
0.79 (0.47, 1.30)
0.89 (0.63, 1.25)
0.88 (0.62, 1.26)
1.62 (0.31, 8.40)
OR (95% CI)
.51
.75
.34
.64
.01
.69
.50
P-value*
Favours aspirin  Favours control or placebo 
1.25 .5 .75 1.5 2.5 5 15
Fig. 6 Effect of aspirin on the primary prevention of major adverse cardiovascular events according to relevant clinical characteristics, based on 
pooled analysis of individual level data from three trials. BP, blood pressure; CI, confidence interval (bars); OR, odds ratio; RA, rheumatoid arthritis
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diabetes who are at increased CVD risk, whereas not rec-
ommended for people at low CVD risk as the potential 
for bleeds likely offsets potential benefits in these people 
[13]. Though the current findings do not justify these rec-
ommendations, it appears the clinical decision to initi-
ate low dose aspirin for primary prevention is a complex 
process and should be individualised and tailored to each 
patient’s baseline CVD and bleeding risk, as these tend 
to differ from one individual to another. Patients prefer-
ences should also be taken into account when making 
the decision. Leggio and colleagues in their review rec-
ommend that when a decision is taken to initiate primary 
CVD prevention, uncoated aspirin formulations with 
higher bioavailability should be prescribed at the lowest 
effective lower dose and concurrently used with proton-
pump inhibitors for those at high risk of gastrointestinal 
bleeding [46]. In addition, concurrent use of nonsteroi-
dal anti-inflammatory drugs should be avoided and those 
with rapid platelet turnover should be considered for 
twice-daily dosing regimen [46].
Strengths and limitations
Several strengths of this review deserve considera-
tion. Compared to previous reviews including the most 
recent one [36], it is the largest and most comprehensive 
review on the topic to date. In total we included 12 tri-
als with additional data contributed by three trials that 
shared their individual level data, hence we had the abil-
ity to examine the efficacy and hazards of aspirin therapy 
for a wider range of cardiovascular end points as well 
as adverse events. We systematically explored for pos-
sible sources of heterogeneity and tested for evidence of 
effect modification using several prespecified study level 
characteristics. This study also had limitations, several of 
which were inherent to the meta-analysis. Definitions of 
some of the clinical outcomes were not consistent across 
all studies, which could potentially have led to biased 
estimates. The definition of MACE used in several of the 
eligible studies included total stroke, which did not dif-
ferentiate between ischaemic and haemorrhagic stroke 
events. Hence, this could have resulted in an underes-
timation of the potential protective effects of aspirin. 
There appeared to be selective reporting by some studies, 
as data on some cardiovascular endpoints and adverse 
events were not reported by some of the included stud-
ies. For example, MACE and all-cause mortality out-
comes were reported in 10 and 8 trials respectively. We 
were unable to perform detailed subgroup analyses by 
clinically relevant subgroups such as appropriate baseline 
CVD risk groups, appropriate treatment dosages, type of 
diabetes, and duration of diabetes because of the limited 
data and inconsistent way of reporting. For example, the 
dosages and timing of aspirin varied considerably across 
the studies. These findings should therefore be inter-
preted with caution given the limitations.
Conclusions
Aspirin has potential benefits in cardiovascular primary 
prevention in diabetes, but these may be counterbal-
anced by an increased bleeding risk. There are sugges-
tions of differential effects of aspirin on cardiovascular 
outcomes by treatment dosage and duration as well as 
smoking status, but more data is required. The use of low 
dose aspirin may need to be individualised and based on 
each individuals baseline CVD and bleeding risk.
Additional file
Additional file 1. Additional appendices.
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